AHA 2025 | OPTIMA-AF: 1 Month vs. 12 Months of Dual Therapy (DOAC + P2Y12) After PCI in Atrial Fibrillation

Concomitant atrial fibrillation (AF) and coronary artery disease is a common occurrence in clinical practice. In these patients, current guidelines recommend 1 month of triple therapy (direct oral anticoagulation [DOAC] + dual antiplatelet therapy [DAPT]) followed by 12 months of dual therapy (DOAC + P2Y12 inhibitor) after percutaneous coronary intervention (PCI). The OPTIMA-AF study assessed whether a shorter regimen — 1 month of DOAC + P2Y12, followed by DOAC monotherapy — could maintain efficacy while reducing the bleeding risk.

This randomized trial, conducted in 75 centers in Japan, included 1088 patients with AF undergoing PCI. The primary endpoint (PEP) was a composite of death, myocardial infarction (MI), or stroke at 1 year. The safety endpoint was the incidence of bleeding or deterioration in quality of life over the same period.

All procedures used Xience stents and intravascular imaging (intravascular ultrasound [IVUS]/optical coherence tomography [OCT]) guidance. Patients received aspirin (ASA) + P2Y12 + DOAC during the periprocedural period. The design included analyses for noninferiority and superiority. Mean age was 75 years, 80% of subjects were men, 94.1% had chronic coronary syndromes, and clopidogrel was used as the P2Y12 inhibitor in 48.5% of cases.

Read also: AHA 2025 | CLOSURE-AF: Left Atrial Appendage Occlusion (LAAO) vs. Medical Therapy in Atrial Fibrillation with High Stroke and Bleeding Risk

In the PEP analysis, there was an absolute event difference of 0.9%, thus meeting the noninferiority criterion (4.5% [1 month] vs. 5.4% [12 months]; hazard ratio [HR] 1.20; 95% confidence interval [CI] 0.70–2.07; p=0.002). Regarding safety, the 1-month arm showed a significant reduction in clinically relevant bleeding (4.8% vs. 9.5%; HR 0.50; 95% CI 0.31–0.80; p=0.004), being superior in this aspect.

Conclusions

In AF patients undergoing PCI, a 1-month regimen of DOAC + P2Y12 inhibitor followed by DOAC monotherapy proved noninferior for ischemic events and halved the incidence of clinically relevant bleeding.

Presented by Yohei Sotomi during the Late-Breaking Science session at AHA 2025, New Orleans, USA.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

Dual Antiplatelet Therapy in Diabetic Patients with AMI: De-Escalation Strategy

Diabetes Mellitus (DM) is a common comorbidity in patients hospitalized for acute coronary syndrome (ACS) of increasing prevalence over the last decade, associated with...

AHA 2025 | OCEAN Study: Anticoagulation vs. Antiplatelet Therapy After Successful Atrial Fibrillation Ablation

After a successful atrial fibrillation (AF) ablation, the need to maintain long-term anticoagulation (AC) remains uncertain, especially considering the very low residual embolic risk...

AHA 2025 | VESALIUS-CV: Evolocumab in High-Cardiovascular-Risk Patients Without Prior MI or Stroke

LDL cholesterol is a well-established factor for cardiovascular disease. Therapy with PCSK9 inhibitors, including evolocumab, has been shown to reduce the risk of cardiovascular...

AHA 2025 | DAPT-MVD: Extended DAPT vs. Aspirin Monotherapy After PCI in Multivessel Disease

In patients with multivessel coronary artery disease who remain stable 12 months after drug-eluting stent (DES) stenting, there is uncertainty as to prolonging dual...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EMERALD II: Non-Invasive Coronary Anatomy and Physiology (CCTA) in ACS Prediction

Despite steady progress in secondary prevention and medical treatment optimization (OMT), acute coronary syndrome (ACS) remains one of the leading causes of cardiovascular morbimortality....

Impact of Balloon Post-Dilation on the Long-Term Durability of Bioprostheses after TAVR

Balloon post-dilation (BPD) during transcatheter aortic valve replacement (TAVR) allows for the optimization of prosthesis expansion and the reduction of residual paravalvular aortic regurgitation....

TAVR in Pure Native Aortic Regurgitation: Are Dedicated Devices Truly Superior?

This systematic meta-analysis assessed the efficacy and safety of transcatheter aortic valve replacement (TAVR) in patients with pure native aortic regurgitation. The emergence of...